ORIGINAL ARTICLESPrognosis comparisons in acute ischemic stroke patients with thrombolysis and nonthrombolysis therapy a retrospective study with larger sample sizeLi, Haojuna; Wu, YupengbAuthor Information aEmergency Department, Xinhua Hospital Affiliated to Medicine School of Shanghai Jiaotong University, Shanghai bDepartment of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China Correspondence to Yupeng Wu, MD, Department of Neurosurgery, The Second Hospital of Hebei Medical University, No. 215, West Heping Road, Shijiazhuang 050017, Hebei, China E-mail: email@example.com Received 15 August, 2017 Revised 24 October, 2017 Accepted 14 November, 2017 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.bloodcoagulation.com). Blood Coagulation & Fibrinolysis: March 2018 - Volume 29 - Issue 2 - p 178-183 doi: 10.1097/MBC.0000000000000685 Buy SDC Metrics Abstract We compared the short-term, middle-term and long-term primary outcomes between thrombolysis and nonthrombolysis therapy in acute ischemic stroke (AIS) patients. Medical records were collected from patients suffered from AIS between 2010 and 2013 and allocated into either the intravenous recombinant tissue plasminogen activator (as rt-PA group) treatment, or non-rt-PA treatment group (as control group). The primary outcomes included a proportion of patients with favorable outcome [as defined with a modified Rankin Scale (mRS) of 0–1], functional independence (mRS of 0–2) or with bad outcome (mRS of 5–6) at 3, 6 and 12 months and the overall mortality. The secondary outcome included the events of intracranial hemorrhage. A total of 357 patients from Xinhua Hospital were selected. At 3-month follow-up, 86 patients in rt-PA vs. 99 in control group had favorable outcome, 105 vs. 122 were independent and 23 vs. 27 had bad outcome. At 6-month follow-up, 101 patients in rt-PA vs. 104 in control group had favorable outcome, 114 vs. 124 were independent and 20 vs. 34 had bad outcome. At 12 months, 104 patients in rt-PA vs. 105 in control group had favorable outcome, 117 vs. 125 were independent and 12 vs. 32 had bad outcome. At the end of 12 months, more deaths occurred in control group (20) than in the rt-PA group (11), but it was not statistically significant. Alteplase treatment in AIS patients showed the superior primary outcomes compared with control group, especially during the middle/long follow-up. Copyright © 2018 YEAR Wolters Kluwer Health, Inc. All rights reserved.